Compare GeneDx Holdings Corp (WGS) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Wix.Com Ltd — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.58B), while Wix.Com Ltd trades at $73.87 (market cap $3.11B). The key difference: Wix.Com Ltd is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| WGS | WIX | |
|---|---|---|
Market Cap | $2.58B | $3.11B |
Sector | Technology | Technology |
52-Week High | $167.51 | $184.24 |
52-Week Low | $34.51 | $40.43 |
Enterprise Value | $2.61B | $4.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
WIX trades at $72.72, down 4.58% amid technical bearish signals and multiple securities class action lawsuits. The company shows revenue growth to $1.99B in 2025 but faces profitability challenges with a negative net income margin of -8.19%. Recent earnings were mixed with Q1 2026 missing expectations while Q2 2026 beat estimates. Cash flow trends show operational strength but significant investing outflows.
Analyst consensus remains positive with 63% buy ratings and $73.36 price target, but legal risks and competitive pressures create headwinds. The stock presents a high-risk opportunity with potential upside if legal issues resolve and AI product execution improves, though current technical weakness suggests caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
